Should you buy CorMedix (CRMD)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Elite Quality Compounder Metrics→Stable
- Earnings Beat Streak Value→Stable
- Death Cross Momentum Risk→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Quality Compounder Metrics
Trip ifROE falls below 30% or the Piotroski F-Score drops below 6 in the next annual report, indicating quality deterioration.
- P2Earnings Beat Streak Value
Trip ifCorMedix misses consensus EPS estimates by more than 10% at its next earnings report.
- P3Death Cross Momentum Risk
Trip ifThe stock closes below the 200-day moving average for more than 90 consecutive days without the death-cross gate clearing.
- P4Short Squeeze Setup Risk
Trip ifShort interest rises above 25% of float while the stock price falls more than 15% from current levels.
- P5Position Sizing Conviction Signal
Trip ifConviction rating drops to the lowest tier at the next data refresh, or ATR volatility exceeds 6%.
How the engine reached this verdict
TrendMatrix's engine output for CorMedix Inc. (CRMD) is STRONG_BUY_WAIT with medium conviction, score 7.2/10 at $8.61. The C-path quality+value combination cleared its gates — quality 9.3 and value 8.6 — with 3.58 asymmetric R:R supporting the read.
BUY_NOW requires death cross (HARD_BLOCK) to clear OR price pulling back to the entry zone of $8.35 with asymmetry crossing 2.5. The verdict flips to HOLD if overall score deteriorates by ~0.7 from sentiment or technical drift.
On the bull side: Strong earnings beat streak (3/4); Strong overall score: 7.2/10; High-quality business. On the bear side: Earnings expected to decline ~84% (cyclical peak); Elevated risk factors; Below 200-MA, MA slope -7.0%/30d (confirmed downtrend). Active engine warnings: V8: Cyclical trap - fwd PE 25x vs trail 4x (6.2x), V9 Gate Failed: DEATH_CROSS:HARD_BLOCK.
The engine's suggested entry zone is $8.35, currently 3.1% above entry. Target $13.22, stop $7.77, asymmetric R:R 3.58. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 1.6% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CRMD — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Strong overall score: 7.2/10
- ▸High-quality business
Bear case
- ▸Earnings expected to decline ~84% (cyclical peak)
- ▸Elevated risk factors
- ▸Below 200-MA, MA slope -7.0%/30d (confirmed downtrend)